Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 1
1985 7
1986 2
1987 1
1988 4
1990 1
1991 1
1992 1
1993 5
1994 3
1995 1
1996 2
1997 3
1998 7
1999 8
2000 14
2001 12
2002 13
2003 10
2004 8
2005 11
2006 7
2007 5
2008 7
2009 8
2010 14
2011 13
2012 19
2013 7
2014 6
2015 11
2016 7
2017 8
2018 8
2019 4
2020 7
2021 17
2022 11
2023 7
2024 6
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

271 results

Results by year

Filters applied: . Clear all
Page 1
Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer's disease.
Gate D, Saligrama N, Leventhal O, Yang AC, Unger MS, Middeldorp J, Chen K, Lehallier B, Channappa D, De Los Santos MB, McBride A, Pluvinage J, Elahi F, Tam GK, Kim Y, Greicius M, Wagner AD, Aigner L, Galasko DR, Davis MM, Wyss-Coray T. Gate D, et al. Nature. 2020 Jan;577(7790):399-404. doi: 10.1038/s41586-019-1895-7. Epub 2020 Jan 8. Nature. 2020. PMID: 31915375 Free PMC article.
Finally, we used machine learning, cloning and peptide screens to demonstrate the specificity of clonally expanded TCRs in the cerebrospinal fluid of patients with Alzheimer's disease to two separate Epstein-Barr virus antigens. These results reveal an adaptive immune resp …
Finally, we used machine learning, cloning and peptide screens to demonstrate the specificity of clonally expanded TCRs in the cerebrospinal …
Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease.
Middeldorp JM. Middeldorp JM. Curr Top Microbiol Immunol. 2015;391:289-323. doi: 10.1007/978-3-319-22834-1_10. Curr Top Microbiol Immunol. 2015. PMID: 26428379 Review.
Epstein-Barr virus (EBV) is widely distributed in the world and associated with a still increasing number of acute, chronic, malignant and autoimmune disease syndromes. ...
Epstein-Barr virus (EBV) is widely distributed in the world and associated with a still increasing number of acute, chronic, malignan …
SARS-CoV-2 infection as a cause of neurodegeneration.
Bonhenry D, Charnley M, Gonçalves J, Hammarström P, Heneka MT, Itzhaki R, Lambert JC, Mannan M, Baig AM, Middeldorp J, Nyström S, Reynolds NP, Stefanatou M, Berryman JT. Bonhenry D, et al. Lancet Neurol. 2024 Jun;23(6):562-563. doi: 10.1016/S1474-4422(24)00178-9. Lancet Neurol. 2024. PMID: 38760096 No abstract available.
Virus and cell RNAs expressed during Epstein-Barr virus replication.
Yuan J, Cahir-McFarland E, Zhao B, Kieff E. Yuan J, et al. J Virol. 2006 Mar;80(5):2548-65. doi: 10.1128/JVI.80.5.2548-2565.2006. J Virol. 2006. PMID: 16474161 Free PMC article.
Changes in Epstein-Barr virus (EBV) and cell RNA levels were assayed following immunoglobulin G (IgG) cross-linking-induced replication in latency 1-infected Akata Burkitt B lymphoblasts. ...Thus, LTIII expression is a characteristic of late EBV replication in both B lymph …
Changes in Epstein-Barr virus (EBV) and cell RNA levels were assayed following immunoglobulin G (IgG) cross-linking-induced replicati …
Virus-modified exosomes for targeted RNA delivery; a new approach in nanomedicine.
Koppers-Lalic D, Hogenboom MM, Middeldorp JM, Pegtel DM. Koppers-Lalic D, et al. Adv Drug Deliv Rev. 2013 Mar;65(3):348-56. doi: 10.1016/j.addr.2012.07.006. Epub 2012 Jul 20. Adv Drug Deliv Rev. 2013. PMID: 22820525 Free PMC article. Review.
Evidence is accumulating that most pluricellular organisms sustain exosome-based communications via inter-cellular exchange of mRNA and miRNAs between cells. We discovered that viruses have found ways to exploit this communication pathway and we argue here that adaptations …
Evidence is accumulating that most pluricellular organisms sustain exosome-based communications via inter-cellular exchange of mRNA and miRN …
Association Between Antibodies That Bind Epstein-Barr Virus (EBV) gp350 and gH/gL and Shedding of EBV in Saliva From Nasopharyngeal Carcinoma Multiplex Family Members in Taiwan.
Liu KL, Hsu WL, Bu W, Yu KJ, Wang CP, Chien YC, Chen TC, Chen CJ, Hildesheim A, Middeldorp JM, Waterboer T, Cohen JI, Coghill AE, Liu Z. Liu KL, et al. Open Forum Infect Dis. 2024 Aug 31;11(9):ofae464. doi: 10.1093/ofid/ofae464. eCollection 2024 Sep. Open Forum Infect Dis. 2024. PMID: 39229285 Free PMC article.
Elevated levels of Epstein-Barr virus (EBV) gp350 and gH/gL antibodies have been associated with a lower risk of developing nasopharyngeal carcinoma (NPC), although the evidence remains inconclusive and unexplained. ...These findings underscore the complexity of virus …
Elevated levels of Epstein-Barr virus (EBV) gp350 and gH/gL antibodies have been associated with a lower risk of developing nasophary …
Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.
Stoker SD, Novalić Z, Wildeman MA, Huitema AD, Verkuijlen SA, Juwana H, Greijer AE, Tan IB, Middeldorp JM, de Boer JP. Stoker SD, et al. J Cancer Res Clin Oncol. 2015 Oct;141(10):1845-57. doi: 10.1007/s00432-015-1969-3. Epub 2015 Apr 29. J Cancer Res Clin Oncol. 2015. PMID: 25920375 Clinical Trial.
Treatment options are limited, and survival is poor. Intratumoural Epstein-Barr virus (EBV) was used as treatment target. In NPC, EBV is present in a latent state, expressing only few non-immunogenic viral products. ...
Treatment options are limited, and survival is poor. Intratumoural Epstein-Barr virus (EBV) was used as treatment target. In NPC, EBV …
Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma.
Hutajulu SH, Kurnianda J, Tan IB, Middeldorp JM. Hutajulu SH, et al. Ther Clin Risk Manag. 2014 Sep 5;10:721-36. doi: 10.2147/TCRM.S47434. eCollection 2014. Ther Clin Risk Manag. 2014. PMID: 25228810 Free PMC article. Review.
Its etiology is unique and multifactorial, involving genetic background, epigenetic, and environment factors, including Epstein-Barr virus (EBV) infection. The presence of EBV in all tumor cells, aberrant pattern of antibodies against EBV antigens in patient sera, and elev …
Its etiology is unique and multifactorial, involving genetic background, epigenetic, and environment factors, including Epstein-Barr viru …
2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19.
Schulman S, Arnold DM, Bradbury CA, Broxmeyer L, Connors JM, Falanga A, Iba T, Kaatz S, Levy JH, Middeldorp S, Minichiello T, Nazy I, Ramacciotti E, Resnick HE, Samama CM, Sholzberg M, Thachil J, Zarychanski R, Spyropoulos AC; International Society on Thrombosis and Haemostasis. Schulman S, et al. J Thromb Haemost. 2024 Jun;22(6):1779-1797. doi: 10.1016/j.jtha.2024.02.011. Epub 2024 Mar 18. J Thromb Haemost. 2024. PMID: 38503600 Free article.
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.
Writing Committee for the REMAP-CAP Investigators; Higgins AM, Berry LR, Lorenzi E, Murthy S, McQuilten Z, Mouncey PR, Al-Beidh F, Annane D, Arabi YM, Beane A, van Bentum-Puijk W, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Burrell A, Buzgau A, Buxton M, Charles WN, Cove M, Detry MA, Estcourt LJ, Fagbodun EO, Fitzgerald M, Girard TD, Goligher EC, Goossens H, Haniffa R, Hills T, Horvat CM, Huang DT, Ichihara N, Lamontagne F, Marshall JC, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Neal MD, Nichol AD, Parke RL, Parker JC, Parry-Billings K, Peters SEC, Reyes LF, Rowan KM, Saito H, Santos MS, Saunders CT, Serpa-Neto A, Seymour CW, Shankar-Hari M, Stronach LM, Turgeon AF, Turner AM, van de Veerdonk FL, Zarychanski R, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Derde LPG, Gordon AC, Webb SA, Lawler PR. Writing Committee for the REMAP-CAP Investigators, et al. JAMA. 2023 Jan 3;329(1):39-51. doi: 10.1001/jama.2022.23257. JAMA. 2023. PMID: 36525245 Free PMC article.
271 results